瑞士羅氏目標晉身全球三大減肥藥企 候選藥進入第三階段臨床
《CNBC》報道,瑞士藥業巨擘羅氏(Roche)正就旗下試驗減肥藥推進後期臨床,爭取晉身全球三大減肥藥企業之列,對板塊龍頭丹麥諾和諾德(NVO.US)及禮來(LLY.US)帶來潛在挑戰。
羅氏行政總裁Teresa Graham周一(22日)在倫敦舉行的業務日上向投資者及分析員稱,她希望向大家強調她對目標是認真的。Graham補充,公司知道如何打入新市場。
羅氏本周較早時間指,其注射減肥藥CT-388進入第三階段臨床。現時羅氏未有在市場上推出任何減肥藥,但Graham稱,目標在2030年前推出有關療程。這包括其與丹麥生科企業Zealand Pharma聯合開發及商業化的候選藥Petrelintide,是兩企53億美元夥伴計劃的一部分。
羅氏副總裁Manu Chakravarthy向《CNBC》就Petrelintide時間表稱,因為正如期推進,公司正全力推動加快推出有關藥物。
報道引述巴克萊醫藥分析師Yihan Li稱,羅氏冀打進減肥藥三甲的目標具潛在可行性,因公司具有廣泛控制體重相關資產,但指明年是相關數據出爐的重要一年。更重要的是,現時減肥藥市場只是二元市場,未知諾和諾德與禮來之間的差距有多大。她補充,其他競爭者的產出料在羅氏加入市場前搶先登場。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.